gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLCgastro-j-1255Research ArticleЛЕКЦИИ И ОБЗОРЫLECTURES AND REVIEWSПрукалоприд в лечении хронических запоров функциональной природыPrucalopride in treatment of functional chronic constipationШептулинА. А.SheptulinA. A.

Шептулин Аркадий Александрович – доктор медицинских наук, профессор кафедры пропедевтики внутренних болезней

19991, Москва, ул. Погодинская, д. 1, стр. 1

arkalshep@gmail.comГБОУ ВПО ПМГМУ им. И.М. Сеченова РосздраваRussian Federation201210022012221913Copyright © Шептулин А.А., 20122012Шептулин А.А.Sheptulin A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/1255

Цель обзора. Провести анализ публикаций, посвященных результатам применения нового прокинетика из группы агонистов 5-НТ4-рецепторов прукалоприда в лечении больных с хроническими запорами функциональной природы.Основные положения. Являясь агонистом5-НТ4-рецепторов, прукалоприд стимулирует моторику толстой кишки и способствует учащению актов дефекации. Многочисленные исследования подтвердили, что на фоне приема прукалоприда в дозе 2 или 4 мг в течение 4–12 нед у больных с хроническими запорами возрастает частота стула и улучшается качество жизни. Важно, что препарат лишен кардиотоксического эффекта и не увеличивает продолжительность интервала Q–T.Заключение. Прукалоприд может быть рекомендован для лечения хронических запоров функциональной природы, в первую очередь у женщин, резистентных к действию слабительных средств.

 

 

The aim of review

The aim of review. To carry out analysis of literature devoted to efficacy assessment of new prokinetic drug – 5-НТ4-receptor agonist prucalopride in treatment of patients with chronic functional constipation.

Original points

Original points. Being an agonist of 5-НТ4- receptors, prucalopride stimulates motility of the large intestine and promotes more frequent bowel movements. Numerous studies confirmed that on a background of prucalopride intake in a dose of 2 or 4 mg for 4-12 wks in patients with chronic constipation defecation frequency increases and quality of life improves. It is important, that the agent has no cardiotoxic effect and does not increase the length of Q–T interval.

Conclusion

Conclusion. Prucalopride can be recommended for treatment of functional chronic constipation, first of all – in women, resistant to laxatives.

хронические запорырезистентность к слабительнымпрукалопридchronic constipationslaxative resistanceprucaloprideReferencesBengtsson M., Ohlsson B. Psychological well-being and symptoms in women with chronic constipation treated with sodium picosulphate // Gastroenterol. Nurs. – 2005. – Vol. 28. – P. 3–12.Bengtsson M., Ohlsson B. Psychological well-being and symptoms in women with chronic constipation treated with sodium picosulphate // Gastroenterol. Nurs. – 2005. – Vol. 28. – P. 3–12.Breier M.R., Prins N.H., Schuurkes J.A. Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs // Neurogastroenterol. Motil. – 2001. – Vol. 13. – P. 465–472.Breier M.R., Prins N.H., Schuurkes J.A. Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs // Neurogastroenterol. Motil. – 2001. – Vol. 13. – P. 465–472.Boyce M., Kerstens R., Beyens G. et al. Cardiovascular safety of prucalopride in healthy subjects: results from a randomised, double-blind, placebo-controlled, cross-over trial // Gut. – 2008. – Vol. 57 (suppl. II). – Abstracts – A282.Boyce M., Kerstens R., Beyens G. et al. Cardiovascular safety of prucalopride in healthy subjects: results from a randomised, double-blind, placebo-controlled, cross-over trial // Gut. – 2008. – Vol. 57 (suppl. II). – Abstracts – A282.Camilleri M., Robinson P., Kerstens R., Vandeplassche M. Safety and adverse event profiles of oral prucalopride: are similar in elderly and adult patients with chronic constipation // Chicago: DDW, 2011. –Abstracts – Mo1304.Camilleri M., Robinson P., Kerstens R., Vandeplassche M. Safety and adverse event profiles of oral prucalopride: are similar in elderly and adult patients with chronic constipation // Chicago: DDW, 2011. –Abstracts – Mo1304.Dennison C., Prasad M., Lloid A. et al. The health-related quality of life and economic burden of constipation // Pharmacoeconomics. – 2005. – Vol. 23. – P. 461–467.Dennison C., Prasad M., Lloid A. et al. The health-related quality of life and economic burden of constipation // Pharmacoeconomics. – 2005. – Vol. 23. – P. 461–467.Dubois D., Kerstens R., Vandeplasscshe L., Tack J. Symptom severity and quality of life in patients with chronic constipation: pooled results from three identical randomized placebo-controlled trials with prucalopride // Gut. – 2008. – Vol. 57 (suppl. II). – Abstracts – A178.Dubois D., Kerstens R., Vandeplasscshe L., Tack J. Symptom severity and quality of life in patients with chronic constipation: pooled results from three identical randomized placebo-controlled trials with prucalopride // Gut. – 2008. – Vol. 57 (suppl. II). – Abstracts – A178.Emmanuel A.V., Kerstens R., Vandeplassche L.M. Prucalopride improves bowel function and colonic transit time in patients with constipation // Chicago: DDW, 2011. – Abstracts – Mo1326.Emmanuel A.V., Kerstens R., Vandeplassche L.M. Prucalopride improves bowel function and colonic transit time in patients with constipation // Chicago: DDW, 2011. – Abstracts – Mo1326.Ford A. An evidence-based systematic review on the management of irritable bowel symdrome // Am. J. Gastroenterol. – 2009. – Vol. 104 (suppl. 1). – P.1–28.Ford A. An evidence-based systematic review on the management of irritable bowel symdrome // Am. J. Gastroenterol. – 2009. – Vol. 104 (suppl. 1). – P.1–28.Galandiuk S., Ryks A., Ausma J., Vandeplassche L. A two-period, double-blind, placebo-controlled study to evaluate the effects of re-treatment of prucalopride (resolor) on efficacy and safety in patients with chronic constipation // Gut. – 2008. – Vol. 57 (suppl. II). – Abstracts – A86.Galandiuk S., Ryks A., Ausma J., Vandeplassche L. A two-period, double-blind, placebo-controlled study to evaluate the effects of re-treatment of prucalopride (resolor) on efficacy and safety in patients with chronic constipation // Gut. – 2008. – Vol. 57 (suppl. II). – Abstracts – A86.Higgins P.D., Johanson J.F. Epidemiology of constipation in North America: a systemic review // Am. J. Gastroenterol. – 1999. – Vol. 99. – P. 750–759.Higgins P.D., Johanson J.F. Epidemiology of constipation in North America: a systemic review // Am. J. Gastroenterol. – 1999. – Vol. 99. – P. 750–759.Johanson J.F., Kralstein J. Chronic constipation: a survey of the patient perspective // Aliment. Pharmacol. Ther. – 2007. – Vol. 25. – P. 599–608.Johanson J.F., Kralstein J. Chronic constipation: a survey of the patient perspective // Aliment. Pharmacol. Ther. – 2007. – Vol. 25. – P. 599–608.Kamm M.A., Emmanuel A.V., Kerstens R., Vandeplassche L. Double-blind, placebo-controlled, cross-over, multiple (N=1) trial to evaluate the effects of pruсalopride in patients with chronic intestinal pseudo-obstruction (CIP) // Gut. – 2008. – Vol. 57 (suppl. II). – Abstracts – A284.Kamm M.A., Emmanuel A.V., Kerstens R., Vandeplassche L. Double-blind, placebo-controlled, cross-over, multiple (N=1) trial to evaluate the effects of pruсalopride in patients with chronic intestinal pseudo-obstruction (CIP) // Gut. – 2008. – Vol. 57 (suppl. II). – Abstracts – A284.Longstreth G.F., Thompson W.G., Chey W.D. et al. Functional bowel disorders // Gastroenterology. – 2006. – Vol. 130. – P.1480–1491.Longstreth G.F., Thompson W.G., Chey W.D. et al. Functional bowel disorders // Gastroenterology. – 2006. – Vol. 130. – P.1480–1491.Mueller-Lissner S., Ryk A., Kerstens R., Vandeplassche L. Pooled efficacy data in elderly patients treated with prucalopride for chronic constipation // Gut. – 2008. – Vol. 57 (suppl. II). – Abstracts – A180.Mueller-Lissner S., Ryk A., Kerstens R., Vandeplassche L. Pooled efficacy data in elderly patients treated with prucalopride for chronic constipation // Gut. – 2008. – Vol. 57 (suppl. II). – Abstracts – A180.Nichols T.W., Beyens G., Ausma J., Kerstens R. A double-blind, placebo-controlled, dose-finding trial to evaluate the efficacy and safety of prucalopride in patients with chronic constipation // Gut. – 2008. – Vol. 57 (suppl. II). – Abstracts – A283.Nichols T.W., Beyens G., Ausma J., Kerstens R. A double-blind, placebo-controlled, dose-finding trial to evaluate the efficacy and safety of prucalopride in patients with chronic constipation // Gut. – 2008. – Vol. 57 (suppl. II). – Abstracts – A283.Ouigley E., Vandeplassche L., Kerstens R., Ausna J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation – a 12-week, randomized, double-blind,Ouigley E., Vandeplassche L., Kerstens R., Ausna J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation – a 12-week, randomized, double-blind,placebo-controlled study // Aliment. Pharmacol. Ther. – 2009. – Vol. 29. – P. 315–328.placebo-controlled study // Aliment. Pharmacol. Ther. – 2009. – Vol. 29. – P. 315–328.Stanghellini V., Kerstens R.., Vandeplassche L.M. Sustained efficacy of oral prucalopride in patients with chronic constipation // Gut. – 2008. – Vol. 57 (suppl. II). – Abstracts – A284.Stanghellini V., Kerstens R.., Vandeplassche L.M. Sustained efficacy of oral prucalopride in patients with chronic constipation // Gut. – 2008. – Vol. 57 (suppl. II). – Abstracts – A284.Stanghellini V., Vandeplassche L.M., Kerstens R., Janssens M. The rеlation between adverse events on day 1 and pharmacodynamic effects on day 1 of treatment with pruсalopride // Chicago: DDW, 2011. – Abstracts– Mo1336.19.Stanghellini V., Vandeplassche L.M., Kerstens R., Janssens M. The rеlation between adverse events on day 1 and pharmacodynamic effects on day 1 of treatment with pruсalopride // Chicago: DDW, 2011. – Abstracts– Mo1336.19.Stewart W.F., Liberman J.N., Sandler R.S. et al. Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features // Am. J. Gastroenterol. – 1999. – Vol. 94. – P. 3530–3540.Stewart W.F., Liberman J.N., Sandler R.S. et al. Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features // Am. J. Gastroenterol. – 1999. – Vol. 94. – P. 3530–3540.Tachtatzis Ph.M., Kham U., Kelly A. et al. Prucalopride for constipation in a tertiary care setting: real life experience // Chicago: DDW, 2011. – Abstracts – Mo1323.Tachtatzis Ph.M., Kham U., Kelly A. et al. Prucalopride for constipation in a tertiary care setting: real life experience // Chicago: DDW, 2011. – Abstracts – Mo1323.Tack J., van Outryve M., Beyens G. et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives // Gut. – 2009. –Vоl. 58. – P. 357–365.Tack J., van Outryve M., Beyens G. et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives // Gut. – 2009. –Vоl. 58. – P. 357–365.Tack J.F., Kerstens R., Vandeplassche L.M. Efficacy and safety of oral prucalopride in female patients with chronic constipation: pooled data of 3 pivotal trials // Chicago: DDW, 2011. – Abstracts – Mo1335.Tack J.F., Kerstens R., Vandeplassche L.M. Efficacy and safety of oral prucalopride in female patients with chronic constipation: pooled data of 3 pivotal trials // Chicago: DDW, 2011. – Abstracts – Mo1335.Tonini M., Pace F. Drugs acting on serotonin receptors for the treatment of functional GI disorders // Gastrointestinal Pharmacology and Therapeutics / Eds. Scarpignato C., di Mario F. – Basel: Karger, 2006. – P. 96–113.Tonini M., Pace F. Drugs acting on serotonin receptors for the treatment of functional GI disorders // Gastrointestinal Pharmacology and Therapeutics / Eds. Scarpignato C., di Mario F. – Basel: Karger, 2006. – P. 96–113.Van de Velde V., Ausma J., Vandeplassche L.M. Pharmacokinetics of pruсalopride (Resolor) in man // Gut. – 2008. – Vol. 57 (suppl. II). – Abstracts – A282.Van de Velde V., Ausma J., Vandeplassche L.M. Pharmacokinetics of pruсalopride (Resolor) in man // Gut. – 2008. – Vol. 57 (suppl. II). – Abstracts – A282.Yost K.J., Haan M.N., Levine R.A. et al. Comparing SF-36 scores across three groups of women with different health profiles // Qual. Life Res. – 2005. – Vol. 14. – P. 1251–1261.Yost K.J., Haan M.N., Levine R.A. et al. Comparing SF-36 scores across three groups of women with different health profiles // Qual. Life Res. – 2005. – Vol. 14. – P. 1251–1261.

The authors declare that there are no conflicts of interest present.